According to the Spanish companies, their partnership will include the genomic and proteomic analysis of hundreds of tumor samples in order to uncover clues about colorectal cancer and how to improve molecular tools for diagnosis and prognosis of the disease.
The initial research portion of the collaboration is expected to last two years, and will require an investment of almost €1 million, the companies said. The effort is being supported by the Catalan Institute of Oncology and the College Hospital Vall d'Hebron, they added.